The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study

Trial Profile

The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs MEDI 3250 (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 01 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2015 Accrual to date is 47% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top